Table 1.
SCI Phase | Type of SCI | Animal Model |
Level of Injury | Injected Cells |
Number of Cells | Application Route | Timing of Transplantation | Tests Used for the Assessment of Recovery | Outcome | Year | Reference |
---|---|---|---|---|---|---|---|---|---|---|---|
Acute | Contusion | Rat | Thoracic | Mouse RA-differentiated ESC–NSC | 1 × 106 | At the lesion epicenter | 9 days PI | BBB | Locomotor recovery | 1999 | [15] |
Contusion | Rat | Thoracic | Human ESC–OPC | 2.5 × 105 or 1.5 × 106 | Rostral and caudal to the lesion epicenter | 7 days PI | BBB and 4 parameter kinematic analyses | Locomotor recovery | 2005 | [23] | |
Contusion | Mouse | Thoracic | Mouse ESC–NSC | 2 × 104 | At the lesion epicenter | 10 days PI | Motor score, platform hang and rope walk | Locomotor recovery | 2005 | [16] | |
Contusion | Rat | Thoracic | Human ESC–OPC | 1.5 × 106 | Rostral and caudal to the lesion epicenter | 7 days PI | BBB | Transplantation per se did not decrease locomotor function | 2006 | [24] # | |
Contusion | Mouse | Thoracic | Mouse ESC–primary and secondary neurospheres | 5 × 105 | At the lesion epicenter | 9 days PI | BMS | Locomotor recovery | 2009 | [17] * | |
Compression | Rat | Thoracic | Mouse ESC-motorneurons + OEC | 1 × 106 | At the lesion epicenter | 9 days PI | BBB | Locomotor recovery | 2009 | [36] | |
Contusion | Rat | Cervical | Human ESC–OPC | 1.5 × 106 | Rostral and caudal to the lesion epicenter | 7 days PI | Forelimb movement scores | Locomotor recovery | 2010 | [30] | |
Compression | Mouse | Thoracic | Mouse ESC–neural aggregates overexpressing L1 | 2 × 105 | Rostral and caudal to the lesion epicenter | 3 days PI | BBB score, foot-stepping angle and rump-height index | Locomotor recovery | 2011 | [20] | |
Contusion | Rat | Thoracic | Human ESC–NSC + Schwann cells | 5 × 105 (NSC or Schwann cells) or 1 × 106 (NSC + Schwann cells) | At the lesion epicenter | 7 days PI | BBB | Locomotor recovery | 2012 | [35] | |
Transection | Rat | Thoracic | Human ESC–NSC in fibrin with a growth factor cocktail | 2 × 106 | At the lesion epicenter | 7 days PI | BBB, 21-point locomotion rating scale, electrophysiological assessment | Locomotor recovery | 2012 | [18] | |
Contusion | Rat; mouse | Thoracic | Human ESC–OPC | Rats: 2.4 × 105 or 2.4 × 106. Mice: 2.5 × 105 to 1 × 106 | Rats: 4 injections at the perimeter of the lesion or 1 injection rostral to the lesion epicenter. Mice: rostral to the lesion epicenter. | 6–8 days PI | None | Locomotor recovery in previous studies (see [23,24]) | 2015 | [25] | |
Contusion | Rat | Thoracic | NG2 and MMP9 positive mouse ESC–NSC | 1 × 106 | At the lesion epicenter | 9 days PI | None | Axonal outgrowth into white matter | 2015 | [32] | |
Contusion | Marmoset | Cervical | OPC-enriched marmoset ESC–NSC | 1 × 106 | At the lesion epicenter | 14 days PI | Open field and bar grip strength test | Locomotor recovery | 2015 | [31] * | |
Contusion | Mouse | Thoracic | Human ESC-derived inhibitory interneuron precursors | 3 × 105 or 6–8 × 105 | Caudal to the injury epicenter | 15 days PI | BMS, Allodynia, Thermal hyperalgesia and bladder functional tests | Absence of locomotor recovery | 2016 | [34] | |
Contusion | Mouse | Thoracic | Mouse ESC–NSC overexpressing BDNF | 1 × 105 | At the lesion epicenter | 7 days PI | BMS | Locomotor recovery | 2016 | [19] | |
Contusion | Rat | Thoracic | Mouse ESC–NSC | 1 × 106 | At the lesion epicenter | 21 days PI | BBB and CBS | Absence of locomotor recovery | 2016 | [33] | |
Contusion | Mouse | Thoracic | Murine iPSC and ESC–primary and secondary neurospheres | 5 × 105 | At the lesion epicenter | 9 days PI | BMS | Locomotor recovery | 2010 | [40] * | |
Contusion | Rat | Thoracic | Mouse iPSC–derived astrocytes | 1 × 105 | At the lesion epicenter | 3–7 days PI | BBB, inclined-plane test, SCANET MV-40, sensory tests | Absence of locomotor recovery | 2011 | [41] | |
Contusion | Marmoset | Cervical | Human iPSC–secondary and tertiary neurospheres | 1 × 106 | At the lesion epicenter | 9 days PI | Open field, bar grip, and cage climbing tests. | Locomotor recovery | 2012 | [42] * | |
Contusion | Mouse | Thoracic | Human iPSC–NSC | 1 × 106 | At the lesion epicenter | 7 days PI | BMS, MEPs | Locomotor recovery | 2012 | [43] | |
Hemisection | Rat | Cervical | Human iPSC–NSC in a fibrin matrix and growth factor cocktail | 1.25 × 106 | Three pairs of injections 0.5 mm apart, at the center, rostral, and caudal to the center of the lesion cavity | 14 days PI | Grid-walking, forelimb grooming and LUAT | Absence of locomotor recovery | 2014 | [44] | |
Compression | Rat | Thoracic | Human iPSC–NSC | 5 × 105 | At the lesion epicenter | 7 days PI | BBB, plantar test, beam walking test, and RotaRod | Locomotor recovery | 2015 | [45] | |
Compression | Mouse | Thoracic | Mouse iPSC–NSC | 2 × 105 | Four injections flanking the injury | 7 days PI | BMS, CatWalk, mechanical and thermal allodynia tests. | Locomotor recovery | 2015 | [46] | |
Contusion | Mouse | Thoracic | Murine iPSC-derived neurospheres | 5 × 105 | At the lesion epicenter | 9 days PI | BMS, RotaRod and DigiGait | Locomotor recovery | 2011, 2015 | [47,48] * | |
Contusion | Mouse | Thoracic | Human iPSC–NSC | 4 × 105 | Rostral and caudal to the lesion epicenter | 7 days PI | BMS and Catwalk | Absence of locomotor recovery | 2015 | [49] | |
Compression | Rat | Thoracic | Human iPSC–NSC | 5 × 105 | At the lesion epicenter | 7 days PI | BBB, plantar test, beam walking test and RotaRod | Locomotor recovery | 2015 | [50] | |
Compression | Rat | Thoracic | Human iPSC-OPC in a hydrogel with RGD and PDGF-A | 8 × 105 | Rostral and caudal to the lesion epicenter | 7 days PI | BBB | Locomotor recovery | 2016 | [51] | |
Contusion | Mouse | Thoracic | Human iPSC–OPC | 5 × 105 | At the lesion epicenter | 9 days PI | BMS, RotaRod and DigiGait | Locomotor recovery | 2016 | [52] * | |
Contusion | Mouse | Thoracic | Human iPSC–NSC treated with γ-secretase inhibitor | 5 × 105 | At the lesion epicenter | 9 days PI | BMS | Locomotor recovery | 2016 | [53] * | |
Contusion | Mouse | Thoracic | Human iPSC–NSC | 5 × 105 | At the lesion epicenter | 9 days PI | BMS | Locomotor recovery (declined when tumors formed) | 2017 | [54] * | |
Compression | Rat | Thoracic | Human iPSC–NSC conditioned with EI-tPA | 1.5 × 106 | At the lesion epicenter | 7 days PI | BBB | Locomotor recovery | 2019 | [55] | |
Contusion | Mouse | Thoracic | Human iPSC–spinal cord–NSC | 5 × 105 | At the lesion epicenter | 9 days PI | BMS, RotaRod and treadmill analysis | Locomotor recovery | 2020 | [56] * | |
Contusion | Mouse | Thoracic | Human iPSC–NSC | 1 × 105 | Rostral to the lesion epicenter | 7 days PI | BMS | Locomotor recovery | 2021 | [57] | |
Contusion | Rat | Thoracic | Human iPSC–NSC + MSC + PA-C | 1.8 × 106 | Rostral, caudal, and at the lesion epicenter | 7 days PI | BBB and Catwalk | Absence of locomotor recovery | 2021 | [58] | |
Chronic | Contusion | Rat | Thoracic | Human ESC–OPC | 2.5 × 105 or 1.5 × 106 | Rostral and caudal to the lesion epicenter | 10 months PI | BBB and four-kinematic analyses | Absence of locomotor recovery | 2005 | [23] |
Contusion | Rat | Cervical | Human iPSC–NSC | 2 × 105 | Rostral and caudal to the lesion epicenter | 30 days PI | LUAT, FRT, allodynia test | Absence of locomotor recovery | 2013 | [59] | |
Contusion | Mouse | Thoracic | Human iPSC–NSC treated with γ-secretase inhibitor | 5 × 105 | At the lesion epicenter | 42 days PI | BMS, RotaRod and treadmill analysis | Locomotor recovery | 2018 | [60] * | |
Compression | Rat | Thoracic | Human iPSC–NSC on Laminin-Coated pHEMA-MOETACl Hydrogel | 3 × 105 | At the lesion epicenter | 35 days PI | BBB, plantar test | Absence of locomotor recovery | 2019 | [61] | |
Accidental SCI | Dog | Thoracic | Canine iPSC–NSC | 2 × 106 | At the lesion epicenter, and one vertebral space caudal and rostral to the lesion | >28 days PI | Neurological and electrophysiological evaluation | Absence of locomotor recovery | 2020 | [62] | |
Contusion | Rat | Thoracic | Glial scar photo-ablation + iPSC–regionally specific spinal pre-OPC | 5 × 105 | Rostral and caudal to the lesion epicenter | 70 days post-injury | BBB | Absence of locomotor recovery | 2021 | [63] | |
Contusion | Rat | Cervical | Human iPSC–NSC | 4 × 105 | Rostral and caudal to the lesion epicenter | 28 days PI | FRT, IBB, and LUAT | Absence of locomotor recovery | 2021 | [64] |
SCI: spinal cord injury; PI: post-injury; RA: retinoic acid; ESC: embryonic stem cells; NSC: neural stem cells; OPC: oligodentrocyte progenitor cells; OEC: olfactory ensheathing cells; NG2: nerve glial antigen 2; MMP9: matrix metalloprotease 9; BDNF: brain-derived neurotrophic factor; RGD: arginine–glycine–aspartate peptide: PDGF-A: platelet-derived growth factor A; EI-tPA: enzymatically inactive tissue-type plasminogen activator; MSC: mesenchymal stem cells; PA-C: pH-responsive polyacetal–curcumin nanoconjugate; pHEMA: poly(2-hydroxyethyl methacrylate); MOETACl: co-monomer (2-(methacryloyloxy) ethyl trimethylammonium chloride; BBB: Basso, Beattie, and Bresnahan test; BMS: Basso mouse scale; CBS: combined behavioral score; MEPs: motor-evoked potentials; LUAT: limb-use asymmetry test; FRT: forelimb reaching task; IBB: Irvine, Beatties and Bresnahan test; GABA: Gamma aminobutyric acid. # Keirstead Laboratory; * Okano Laboratory.